Ultimovacs is a norwegian clinical phase biotech with a universal cancer vaccine as its lead product. Today the company reported to the market that in march it will share topline data from its randomized phase 2 trial INITIUM for its lead product UV1 , a universal cancer vaccine to be used in combination with checkpoint inhibitors. The stock is at the...
An average Q3 report for Photocure today giving some selling action, painting up the framework for a nice inverted head & shoulders formation within the long uptrend of the stock.
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data • UV1/pembrolizumab results in 30% complete responses plus 30% partial responses • Good safety and tolerability profile supports use of UV1 in combination treatments • Data to be presented at ASCO and abstract to be discussed in webcast on May...
AZTY reported sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the first quarter of 2021. Highlights from Q1 2021 · ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million) · Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million in Q1 2020) ·...
Relentless buying of #PhysicalSilver causes a solid higher low to be set in the silver chart
Photocure breaking free upwards from important 100 NOK resistance and heads for analyst BUY recommendations at 130+
If the stock breaks through 50 day SMA it looks like it could start a nice bullish movement
Almost like a machine, we seem to get repeated instances of these strong drops, followed by flat trading, and then a jump back up to the start level. I call this the reversed SEMI BART pattern, as it is not quite as flat and defined as we got used to seeing in Bitcoin, but still has some of the hallmarks of the pattern.
SOFTOX HAS COMPLETED ENROLMENT OF SOFTOX WOUND IRRIGATION SOLUTION CONFIRMATORY STUDY (SWIS-02) SoftOx Solutions AS ("SoftOx") is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation...
Nanovector ASA Nordic Nanovector - Q4’20 report: Pace of recruitment for PARADIGME picking up
Kitron increases its 2025 revenue target from NOK 5 billion to NOK 6 billion. The company also raises its 2025 EBIT margin target from 7 to 8 percent.
Silver may have a significant upside in 2021
Delivery platform unicorn Glovo chooses StrongPoint as preferred supplier for grocery picking solutions StrongPoint today announces that Glovo, the on-demand meal and grocery delivery platform available in 22 countries and one of Europe’s leading technology unicorns (a valuation of over USD 1 billion), has chosen StrongPoint as a preferred supplier for grocery...
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, ...
Interesting to see Q4 report for ArcticZymes to learn more about the use of their cod enzymes in Covid 19 vaccines
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA -- FDA sets PDUFA date of July 17, 2021 --
Look for weekly close above 37